These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 32447810)

  • 1. A retrospective, observational multicenter study of 141 patients treated with ustekinumab 90 mg.
    Llamas-Velasco M; Baniandrés O; Rivera R; Reymundo Jimenez A; Hospital M; García Zamora E; González-Cantero Á; Andrés Lencina JJ; Daudén E; de la Cueva P
    Dermatol Ther; 2020 Jul; 33(4):e13678. PubMed ID: 32447810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and safety of ustekinumab 90 mg in patients weighing 100 kg or less: a retrospective, observational, multicenter study.
    Del Alcázar E; Ferran M; López-Ferrer A; Notario J; Vidal D; Riera J; Aparicio G; Gallardo F; Vilarrasa E; Alsina M; Puig L; Ferrándiz C; Carrascosa JM
    J Dermatolog Treat; 2020 May; 31(3):222-226. PubMed ID: 30883242
    [No Abstract]   [Full Text] [Related]  

  • 3. Epidermal Hyperproliferation With Less Prominent Dermal Inflammation Is the Unique Histopathological Feature of the Refractory Lesions in Psoriasis Treated With Ustekinumab.
    Kim M; Yang S; Kim BR; Youn SW
    Am J Dermatopathol; 2022 Apr; 44(4):267-271. PubMed ID: 34726183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ustekinumab does not increase body mass index in patients with chronic plaque psoriasis: a prospective cohort study.
    Gisondi P; Conti A; Galdo G; Piaserico S; De Simone C; Girolomoni G
    Br J Dermatol; 2013 May; 168(5):1124-7. PubMed ID: 23320916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of ustekinumab in patients with psoriatic arthritis in a real-world, multicenter study.
    Azuaga AB; Frade-Sosa B; Laiz A; Estrada P; Prior-Español A; Horcada L; Polino L; Moreno M; Moragues C; Urruticoechea-Arana A; Sellas A; Tandaipan JL; Torrente-Segarra V; Garcia-Miguel J; Ros I; Ordoñez S; Moya P; Reina D; Mateo-Soria L; Fito C; Beltrán E; Pujol M; Cuervo AM; Cañete JD; Ramírez J;
    Clin Rheumatol; 2020 Oct; 39(10):2963-2971. PubMed ID: 32285259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ixekizumab vs ustekinumab for skin clearance in patients with moderate to severe psoriasis after a year of treatment: Real-world practice.
    Herrera-Acosta E; Garriga-Martina GG; Suárez-Pérez JA; Martínez-García E; Herrera-Ceballos E
    Dermatol Ther; 2020 Nov; 33(6):e14202. PubMed ID: 32808703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Greater cumulative benefits from ixekizumab versus ustekinumab treatment over 52 weeks for patients with moderate-to-severe psoriasis in a randomized, double-blinded phase 3b clinical trial.
    Blauvelt A; Lomaga M; Burge R; Zhu B; Shen W; Shrom D; Dossenbach M; Pinter A
    J Dermatolog Treat; 2020 Mar; 31(2):141-146. PubMed ID: 30799638
    [No Abstract]   [Full Text] [Related]  

  • 8. Liver Injury in Psoriasis Patients Receiving Ustekinumab: A Retrospective Study of 44 Patients Treated in the Clinical Practice Setting.
    Llamas-Velasco M; Concha-Garzón MJ; García-Diez A; Daudén E
    Actas Dermosifiliogr; 2015; 106(6):470-6. PubMed ID: 25912374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risankizumab vs. ustekinumab for plaque psoriasis: a critical appraisal.
    Al-Janabi A; Jabbar-Lopez ZK; Griffiths CEM; Yiu ZZN
    Br J Dermatol; 2019 Jun; 180(6):1348-1351. PubMed ID: 30632140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study.
    Reich K; Pinter A; Lacour JP; Ferrandiz C; Micali G; French LE; Lomaga M; Dutronc Y; Henneges C; Wilhelm S; Hartz S; Paul C;
    Br J Dermatol; 2017 Oct; 177(4):1014-1023. PubMed ID: 28542874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up.
    Langley RG; Lebwohl M; Krueger GG; Szapary PO; Wasfi Y; Chan D; Hsu MC; You Y; Poulin Y; Korman N; Prinz JC; Reich K;
    Br J Dermatol; 2015; 172(5):1371-83. PubMed ID: 25307931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of ustekinumab treatment in elderly patients with psoriasis.
    Hayashi M; Umezawa Y; Fukuchi O; Ito T; Saeki H; Nakagawa H
    J Dermatol; 2014 Nov; 41(11):974-80. PubMed ID: 25346301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse Medical Conditions Across Treatment Options in Patients With Psoriasis: A Claims-Based Analysis.
    Wu JJ; Armstrong A; Singh R; Cloutier M; Gauthier-Loiselle M; Gagnon-Sanschagrin P; Arikan D; Fleischer A; Guérin A; Ganguli A
    J Drugs Dermatol; 2018 Nov; 17(11):1211-1218. PubMed ID: 30500143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
    Gordon KB; Strober B; Lebwohl M; Augustin M; Blauvelt A; Poulin Y; Papp KA; Sofen H; Puig L; Foley P; Ohtsuki M; Flack M; Geng Z; Gu Y; Valdes JM; Thompson EHZ; Bachelez H
    Lancet; 2018 Aug; 392(10148):650-661. PubMed ID: 30097359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years.
    Kimball AB; Gordon KB; Fakharzadeh S; Yeilding N; Szapary PO; Schenkel B; Guzzo C; Li S; Papp KA
    Br J Dermatol; 2012 Apr; 166(4):861-72. PubMed ID: 22356258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation Between Dermatology Life Quality Index and Psoriasis Area and Severity Index in Patients with Psoriasis Treated with Ustekinumab.
    Hesselvig JH; Egeberg A; Loft ND; Zachariae C; Kofoed K; Skov L
    Acta Derm Venereol; 2018 Mar; 98(3):335-339. PubMed ID: 29110019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ustekinumab for the treatment of moderate to severe psoriasis.
    Gospodarevskaya E; Picot J; Cooper K; Loveman E; Takeda A
    Health Technol Assess; 2009 Oct; 13 Suppl 3():61-6. PubMed ID: 19846031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exacerbation of atopic dermatitis symptoms by ustekinumab in psoriatic patients with elevated serum immunoglobulin E levels: Report of two cases.
    Ishiuji Y; Umezawa Y; Asahina A; Fukuta H; Aizawa N; Yanaba K; Nakagawa H
    J Dermatol; 2018 Jun; 45(6):732-734. PubMed ID: 29569296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial.
    Langley RG; Tsai TF; Flavin S; Song M; Randazzo B; Wasfi Y; Jiang J; Li S; Puig L
    Br J Dermatol; 2018 Jan; 178(1):114-123. PubMed ID: 28635018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biological treatments for paediatric psoriasis : a retrospective observational study on biological drug survival in daily practice in childhood psoriasis.
    Phan C; Beauchet A; Burztejn AC; Severino-Freire M; Barbarot S; Girard C; Lasek A; Reguiai Z; Hadj-Rabia S; Abasq C; Brenaut E; Droitcourt C; Perrussel M; Mallet S; Phan A; Lacour JP; Khemis A; Bourrat E; Chaby G; Deborde R; Plantin P; Maruani A; Piram M; Maccari F; Fougerousse AC; Kupfer-Bessaguet I; Balguérie X; Barthelemy H; Martin L; Quiles-Tsimaratos N; Mery-Brossard L; Pallure V; Lons-Danic D; Bouilly-Auvray D; Beylot-Barry M; Puzenat E; Aubin F; Mahé E; ;
    J Eur Acad Dermatol Venereol; 2019 Oct; 33(10):1984-1992. PubMed ID: 30883928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.